• 1. In metastatic melanoma:
• Your Colleagues Responded
• A. Anti-PDL1 therapy is approved as a monotherapy as a front-line option

  0%
• B. Anti-PDL1 therapy is approved only as a second line option after ipilimumab

  0%
• C. Combination anti-CTLA1 and anti-PD-1 is approved as after progression on ipilimumab

  0%
• D. A & B

  0%
• E. A, B & C

  0%

• 2. For patients with lung cancer:
• Your Colleagues Responded
• A. Nivolumab is approved as a front-line option

  0%
• B. Pembrolizumab is approved as a front-line option regardless of PDL-1 status

  0%
• C. Nivolumab requires PDL-1 testing prior to treatment

  0%
• D. Immunotherapy is only indicated as a second-line option

  0%
• E. Pembrolizumab requires PDL-1 testing in both front-line and second line therapy

  0%

• 3. For bladder cancer:
• Your Colleagues Responded
• A. Immunotherapy is indicated after progression on platinum based therapy

  0%
• B. Immunotherapy requires PDL-1 testing

  0%
• C. Immunotherapy is approved prior to platinum failure

  0%
• D. Immunotherapy is approved in the adjuvant setting

  0%

• 4. Nivolumab is approved in the following indication:
• Your Colleagues Responded
• A. Classical Hoddkins disease after failure of chemotherapy

  0%
• B. Non-Hodgkins lymphoma after failure of chemotherapy

  0%
• C. Classical HD after progression on chemotherapy and HDT/ASCR

  0%
• D. Classical HD after HDT/ASCR and brentuximab vedotin

  0%
• E. A & B

  0%

• 5. Immunotherapy with checkpoint inhibitors in kidney cancer:
• Your Colleagues Responded
• A. Is superior to everolimus

  0%
• B. Is approved in the front-line setting

  0%
• C. Is approved after progression on VEGF-targeted therapy

  0%
• D. Is approved in combination with VEG-F targeted therapy

  0%
• E. A & C

  0%